Answers are grounded in this paper and cite their sources.
Retrospective study evaluates determinants and biomarkers for chemotherapy response in advanced NSCLC, suggesting implications for patient management.
OBJECTIVE: To evaluate clinical determinants and predictive biomarkers for response to platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: = 146) according to RECIST version 1.1. Clinical characteristics, pre-chemotherapy inflammatory indexes [neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR)], tumor markers [carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1)], and nutritional indicators [albumin (ALB), hemoglobin (HGB)] were analyzed. CONCLUSION: ECOG score ≥2, stage IV disease, multiple metastases, and liver metastases negatively impact chemotherapeutic response, whereas treatment continuity is protective. Baseline NLR, PLR, CEA, CYFRA21-1, ALB, and HGB show predictive utility. A favorable chemotherapeutic response is associated with significantly enhanced survival.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: